1、投稿方式：在线投稿。

2、刊内网址：（202402期）

https://onlinelibrary.wiley.com/journal/27709140

https://journal.hep.com.cn/malignancyspectrum

https://mc.manuscriptcentral.com/malignancyspectrum

（投稿系统）

3、刊内邮箱：MSP2@pub.hep.cn

tuwf@hep.com.cn

wangzi1@hep.com.cn

4、刊内电话：010-58581063；58582120

5、出刊日期：季刊，逢季末月出版。

2024年8月30日星期五

《肿瘤学全景（英文）》征稿

【微信公众号“高教学术（gaojiaoxueshu）”信息】

Malignancy Spectrum（《肿瘤学全景》）是由高等教育出版社主办的全新英文期刊，着眼于肿瘤学领域的全学科建设，聚焦肿瘤科学领域的重大热点问题，注重肿瘤学与相关学科的交叉融合发展。主编詹启敏院士是国际知名肿瘤学专家，长期致力于肿瘤分子生物学和肿瘤转化医学研究。

本刊充分考虑学科发展特点，设立六大板块：

1.肿瘤预防及早诊早治；

2.肿瘤的发生演进与转移；

3.肿瘤代谢、免疫及微环境；

4.生物信息工程、系统生物学与肿瘤学；

5.肿瘤治疗学及转化医学研究；

6.老年肿瘤学、肿瘤康复学与支持治疗学。

研究范围覆盖基础、转化和临床领域，涵盖肿瘤的发生发展、治疗和康复研究，致力于跨领域合作和前沿技术交叉融合，旨在引领肿瘤学及交叉学科的行业发展。

期刊主办单位及出版单位高等教育出版社是中国唯一获得世界知识产权组织“世界知识产权组织创意金奖——单位奖”的中国单体出版机构，获得中国出版政府奖、中华优秀出版物奖、“五个一工程”奖和全国优秀教材奖等重要奖项，综合实力处于中国出版行业领先地位，具有广泛知名度和国际影响力。主办、合办包括《思想理论教育导刊》《中国大学教学》《中国外语》《中国编辑》《马克思主义理论学科研究》及“前沿”系列英文学术期刊（28种）等各类期刊48种，形成了学术期刊群，其中28种“前沿”系列英文学术期刊中的13种被SCI收录，6种被Ei收录，2019年入选“中国科技期刊卓越行动计划”集群化试点1项、重点期刊1项、梯队期刊6项。期刊规模和影响力位居国内前列，在服务高校学科专业建设和人才培养，展示中国学术、传播中国声音方面发挥了重要作用。

Malignancy Spectrum入选2022年度“中国科技期刊卓越行动计划高起点新刊项目”。欢迎投稿！投稿链接：

https://mc.manuscriptcentral.com/malignancyspectrum

Malignancy Spectrum主页：

https://onlinelibrary.wiley.com/journal/27709140

编辑部联系人：王孜、涂文凤

邮箱：MSP2@pub.hep.cn

电话：010-58582120

《肿瘤学全景（英文）》投稿指南

Authors guidelines

【官网信息】

Submission and Peer Review Process

Once the submission materials have been prepared in accordance with the Author Guidelines, manuscripts should be submitted online at ScholarOne Manuscripts.

For help with submissions, please contact: MSP2@pub.hep.cn

This journal does/does not charge submission fees.

Article Preparation Support

Wiley Editing Services offers expert help with English Language Editing, as well as translation, manuscript formatting, figure illustration, figure formatting, and graphical abstract design – so you can submit your manuscript with confidence.

Also, check out our resources for Preparing Your Article for general guidance about writing and preparing your manuscript.

Preprint your manuscript on Authorea

You can now opt to seamlessly preprint your manuscript at submission, through Wiley’s Under Review service, powered by Authorea. Make your work citable and discoverable, before it is accepted or published.

Free format submission

Malignancy Spectrum now offers Free Format submission for a simplified and streamlined submission process.

Before you submit, you will need:

Your manuscript: this should be an editable file including text, figures, and tables, or separate files—whichever you prefer. All required sections should be contained in your manuscript, including abstract, introduction, methods, results, and conclusions. Figures and tables should have legends. Figures should be uploaded in the highest resolution possible. If the figures are not of sufficiently high quality your manuscript may be delayed. References may be submitted in any style or format, as long as it is consistent throughout the manuscript. Supporting information should be submitted in separate files. If the manuscript, figures or tables are difficult for you to read, they will also be difficult for the editors and reviewers, and the editorial office will send it back to you for revision. Your manuscript may also be sent back to you for revision if the quality of English language is poor.

An ORCID ID, freely available at https://orcid.org. (Why is this important? Your article, if accepted and published, will be attached to your ORCID profile. Institutions and funders are increasingly requiring authors to have ORCID IDs.)

The title page of the manuscript, including:

Your co-author details, including affiliation and email address. (Why is this important? We need to keep all co-authors informed of the outcome of the peer review process.)

Statements relating to our ethics and integrity policies, which may include any of the following (Why are these important? We need to uphold rigorous ethical standards for the research we consider for publication):

data availability statement

funding statement

conflict of interest disclosure

ethics approval statement

patient consent statement

permission to reproduce material from other sources

clinical trial registration

更多详情：

……

https://onlinelibrary.wiley.com/page/journal/27709140/homepage/author-guidelines